• Are pharmaceuticals still inexpensive in Norway? : a comparison of prescription drug prices in ten European countries 

      Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Report, Research report, 2010-05)
      In this report we compare prices of pharmaceuticals between Norway and nine Western European countries (Austria, Belgium, Denmark, Finland, Germany, Ireland, the Netherlands, Sweden and United Kingdom). The purpose is to ...
    • Can competition reduce quality? 

      Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper;9/2012, Working paper, 2012-03)
      We study the effect of competition on quality in markets such as health care, long-term care and education, when providers choose both prices and quality in a setting of spatial competition. We offer a novel mechanism ...
    • Comparing pharmaceutical prices in Europe : a comparison of prescription drug prices in Norway with nine Western European countries 

      Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Report;2011:11, Research report, 2011-10)
      In this report we compare prices of pharmaceuticals between Norway and the following nine Western European countries: Austria, Belgium, Denmark, Finland, Germany, Ireland, the Netherlands, Sweden and United Kingdom. We use ...
    • Competing with precision: incentives for developing predictive biomarker tests 

      Brekke, Kurt Richard; Dalen, Dag Morten; Straume, Odd Rune (Peer reviewed; Journal article, 2023)
      We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose, we develop a two-dimensional spatial framework ...
    • Competition and quality in regulated markets with sluggish demand 

      Brekke, Kurt Richard; Cellini, Roberto; Siciliani, Luigi; Straume, Odd Rune (Discussion paper, Working paper, 2008-08)
      We investigate the effect of competition on quality in regulated markets (e.g., health care, higher education, public utilities), using a Hotelling framework, in the presence of sluggish demand. We take a differential game ...
    • Competition and quality in regulated markets: a differential-game approach 

      Brekke, Kurt Richard; Straume, Odd Rune; Siciliani, Luigi; Cellini, Roberto (Discussion paper, Working paper, 2008-02)
      We investigate the effect of competition on quality in regulated markets (e.g., health care, higher education, public utilities) taking a differential game approach, in which quality is a stock variable. Using a Hotelling ...
    • Competition and waiting times in hospital markets 

      Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper, Working paper, 2007-03)
      This paper studies the impact of hospital competition on waiting times. We use a Salop-type model, with hospitals that differ in (geographical) location and, potentially, waiting time, and two types of patients; high-benefit ...
    • Diffusion of pharmaceuticals : cross-country evidence of anti-TNF drugs 

      Brekke, Kurt Richard; Dalen, Dag Morten; Holmås, Tor Helge (Discussion paper;7/2013, Working paper, 2013-03)
      This paper studies the diffusion of biopharmaceuticals across European countries, focusing on anti-TNF drugs, which are used to treat autoimmune diseases (e.g., rheumatism, psoriasis). We use detailed sales information on ...
    • Direct to consumer advertising in pharmaceutical markets 

      Brekke, Kurt Richard; Kuhn, Michael (Working paper, Working paper, 2005-02)
      We study effects of direct-to-consumer advertising (DTCA) in the prescription drug market. There are two pharmaceutical firms providing horizontally differentiated (branded) drugs. Patients differ in their susceptability ...
    • Er legemidler billig i Norge? : en sammenligning av priser på reseptpliktige legemidler mellom Norge og ni vest-europeiske land 

      Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Rapport, Research report, 2008-05)
      I denne rapporten sammenlignes priser på legemidler i Norge med priser på tilsvarende legemidler i følgende ni referanseland: Belgia, Danmark, Finland, Irland, Nederland, Storbritannia, Sverige, Tyskland og Østerrike. ...
    • Er legemidler fremdeles billig i Norge? : en sammenligning av priser på reseptpliktige legemidler mellom Norge og ni vest-europeiske land 

      Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Rapport, Research report, 2009-04)
      Rapporten sammenligner priser på legemidler i Norge med priser på tilsvarende legemidler i følgende ni referanseland: Belgia, Danmark, Finland, Irland, Nederland, Storbritannia, Sverige, Tyskland og Østerrike. Utvalget ...
    • Excessive Pricing of Pharmaceuticals : What are the drivers leading to excessive pricing in the Norwegian pharmaceutical market? 

      Huseby, Nora; Larsson, Peter Nordbø (Master thesis, 2021)
      Millions of people depend on drugs in their everyday life to improve their life quality or even survive. Recently there has been an increase in the number of cases where prices of patented and generic pharmaceuticals ...
    • Horizontal mergers and product quality 

      Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper;4/2014, Working paper, 2014-02)
      Using a spatial competition framework with three ex ante identical firms, we study the effects of a horizontal merger on quality, price and welfare. The merging firms always reduce quality. They also increase prices if ...
    • Hospital competition and quality with regulated prices 

      Brekke, Kurt Richard; Straume, Odd Rune; Siciliani, Luigi (Discussion paper, Working paper, 2008-02)
      We analyse the effect of competition on quality in hospital markets with regulated prices, considering both the effect of free patient choice (monopoly versus competition) and increased competition through lower transportation ...
    • Hospital Competition in a National Health Service: Evidence from a Patient Choice Reform 

      Brekke, Kurt Richard; Canta, Chiara; Siciliani, Luigi; Straume, Odd Rune (Peer reviewed; Journal article, 2021)
    • Hospital competition with soft budgets 

      Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper;6/2012, Working paper, 2012-03)
      We study the incentives for hospitals to provide quality and expend cost-reducing effort when their budgets are soft, i.e., the payer may cover deficits or confiscate surpluses. The basic set up is a Hotelling model with ...
    • Hospital mergers : a spatial competition approach 

      Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper;8/2013, Working paper, 2013-04)
      Using a spatial competition framework with three ex ante identical hospitals, we study the effects of a hospital merger on quality, price and welfare. The merging hospitals always reduce quality, but the non-merging hospital ...
    • Hospital mergers with regulated prices 

      Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper;21/2014, Working paper, 2014-05)
      We study the effects of a hospital merger using a spatial competition framework with semialtruistic hospitals that invest in quality and expend cost-containment effort facing regulated prices. We find that the merging ...
    • Konkurranse i spesialisthelsetjenesten 

      Andersen, Christian; Brekke, Kurt Richard; Kjerstad, Egil; Kristiansen, Frode; Straume, Odd Rune; Sunnevåg, Kjell J. (Rapport, Research report, 2006-09)
      Rapporten diskuterer om konkurranse i sykehussektoren er ønskelig, hvordan konkurranse kan oppnås, og hvilke effekter det har. Diskusjonen er organisert i tre deler. I del 1 diskuteres markedssvikt i helsesektoren, og det ...
    • Margins and market shares : pharmacy incentives for generic substitution 

      Brekke, Kurt Richard; Straume, Odd Rune; Holmås, Tor Helge (Discussion paper, Working paper, 2010-07)
      We study the impact of product margins on pharmacies incentive to promote generics instead of brand-names. First, we construct a theoretical model where pharmacies can persuade patients with a brand-name prescription to ...